Plidan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plidan

Quick Facts

Property Description
Active ingredient Diazepam
Form Tablet, Oral Solution, Injectable Solution, Rectal Gel
Pharmacological class Benzodiazepine derivative, CNS Depressant
Common use Relief of anxiety, muscle spasm, and seizures
Origin Synthetic compound

What Pharmacological Class Does Plidan Belong To?

Plidan is a pharmaceutical preparation whose sole active ingredient is Diazepam, a synthetic compound classified as a Benzodiazepine derivative. This designation places Plidan within the broader group of Central Nervous System (CNS) Depressants. Pharmacological studies have widely confirmed its efficacy in mediating nerve signals. The drug is chemically designed to reduce overactivity in the brain and spinal cord, acting as a functional modulator of inhibitory nerve pathways. The chemical entity Diazepam is clinically recognized as a long-acting Benzodiazepine, an attribute that differentiates it from shorter-acting analogues in the duration for which its stabilizing effects are sustained within the body.

The General Purpose and Forms of Plidan

The general purpose of Plidan is to utilize its core CNS depressant properties to produce well-documented anxiolytic (calming), skeletal muscle relaxant, and anticonvulsant effects. This means the medication offers broad stabilization by helping to quiet overactive nerve signaling, often used in scenarios requiring generalized relaxation. The medication is presented as a single-ingredient product in several distinct dosage form(s) to accommodate varying patient needs. These preparations include the common tablet for oral administration, an oral solution, and sterile solutions for parenteral (intravenous or intramuscular) administration, alongside a specialized rectal gel. This array of delivery formats ensures the active ingredient is accessible via multiple routes of administration, allowing the core therapeutic properties of Diazepam to be effectively and efficiently applied, particularly when rapid action is necessary.

Regulatory References

  1. National Library of Medicine: MedlinePlus

What side effects are possible with Plidan?

Possible Side Effects and Safety Information

The official safety profile of Plidan (Diazepam) is primarily characterized by effects related to its central nervous system (CNS) depressant activity, as documented in governmental regulatory sources. The most common adverse reactions, defined as affecting up to 1 in 10 people, include sedation, somnolence, drowsiness, fatigue, ataxia (unsteady gait), and confusion. These effects are often most noticeable at the start of treatment or following an increase in the prescribed amount.

Adverse reactions are classified by the affected physiological system. Documented effects extend to Psychiatric Disorders (e.g., depression, paradoxical reactions like agitation), Gastrointestinal Disorders (e.g., nausea, dry mouth), Eye Disorders (e.g., blurred vision), and in rare cases, Hepatobiliary Disorders (e.g., jaundice) and Vascular Disorders (hypotension).

Serious adverse reactions officially documented include the risk of respiratory depression and the potential for physical and psychological dependence, particularly associated with long-term use and higher doses. Other serious events documented include hepatic failure and anaphylaxis.

Specific population safety considerations are noted in official labeling. Older adults have an increased risk of CNS effects such as sedation and ataxia, which elevates the risk of falls. Furthermore, the medication is formally contraindicated (should not be used) in individuals with certain severe pre-existing conditions, including severe respiratory insufficiency, severe hepatic impairment, and myasthenia gravis.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations: The primary presentation of overdose is central nervous system depression, which can range from somnolence, ataxia, lethargy, and slurred speech to diminished reflexes and a coma-like state [US FDA Label, MedlinePlus].
Physiological systems affected (as stated in label): The CNS and Respiratory System are primarily affected, potentially leading to profound sedation, respiratory depression, and apnea [US FDA Label, SmPC]. Hypotension has also been officially documented [SmPC].
Dose-related or exposure-related factors (if applicable): The risks of coma and death are significantly increased with the concomitant use of other CNS depressants, particularly alcohol or opioids [US FDA Label].
Population-specific overdose notes (if applicable): Elderly patients are more susceptible to the CNS depressant effects and have a higher documented risk of developing coma and respiratory failure [SmPC, Research]. Patients with hepatic or renal impairment may also face an increased risk due to potential drug accumulation [US FDA Label].
Emergency-response statements (as written in official documents): Management is primarily symptomatic and supportive [SmPC]. Monitoring of vital signs and respiratory support is essential [MedlinePlus]. The specific antagonist Flumazenil may be used by professionals but is not recommended for routine use in acute toxicity [US FDA Label].
When immediate medical help is required (label-derived phrasing only): Seek immediate medical help right away [MedlinePlus]. Urgent assistance is required for signs such as shallow or slowed breathing or excessive sleepiness [US FDA Label].

Overdose Classifications (High-level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): Manifestations are officially classified on a spectrum from mild CNS depression to severe or life-threatening outcomes, including coma and cardiac arrest [US FDA Label, SmPC].
Regulatory basis (EMA / FDA / etc.): Information is based on official documents, including US FDA Prescribing Information and European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) [Various Sources].
Overdose-context constraints (as defined in official documents): Use of the antagonist Flumazenil must be considered with caution as it may precipitate acute withdrawal reactions [US FDA Label].

Connection to the overall overdose profile (2–4 sentences):

The regulatory profile explicitly defines Plidan overdose by documenting the progressive central nervous system depression and the severe complications that necessitate urgent medical response. The official framework mandates that immediate medical attention be sought for any suspected overdose, especially if profound sedation or respiratory compromise is evident. Management described in regulatory documents is focused on supportive care, continuous vital sign monitoring, and stabilizing the patient.

Therapeutic Uses of Plidan

What Plidan Treats: Main Uses and Benefits

The primary therapeutic role of Plidan is to provide supportive symptomatic relief across several key clinical domains characterized by symptoms of increased neurological or muscular activity. The medication is considered relevant when symptoms become functionally disruptive or interfere with functional stability in acute, uncontrolled episodes.

Plidan is commonly used to help with symptoms related to anxiety disorders, muscle spasms and spasticity associated with chronic neurologic conditions, acute seizure episodes (such as status epilepticus), and the severe manifestations of acute alcohol withdrawal syndrome.

“The medication may provide support to ease distress and assist with functional stability during difficult episodes.”

Therapeutic Focus Areas

Plidan helps address symptom clusters that may become intense or disruptive, such as generalized tension, fear, and agitation, as well as pronounced muscle stiffness and convulsive activity. It is relevant in contexts marked by increased discomfort or tension, providing supportive relief that helps ease the overall symptom burden.


Quick Fact: Relief for Heightened Activity

Therapeutic Benefit Common Clinical Scenario
Anxiolysis Supportive relief for severe tension and agitation.
Muscle Relaxation Supportive management of spasticity in conditions like cerebral palsy.
Anticonvulsant Support Assisting with acute or recurrent seizure clusters.
Stabilization Applied in addressing symptoms during acute alcohol withdrawal.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Plidan (Diazepam) eligibility is strictly defined by regulatory authorities based on patient age, pre-existing conditions, and physiological status.

Contraindications and Restrictions

Classification Who Must Not Use Plidan (Contraindicated)
Absolute Contraindications Patients with known hypersensitivity to benzodiazepines, myasthenia gravis, severe respiratory insufficiency, sleep apnea syndrome, and severe hepatic insufficiency [1.1, 2.1].
Age Restriction Infants under 6 months of age are prohibited from using oral formulations due to lack of established safety data [1.1].

Age and Organ Function Eligibility

  • Adults (18+): Use is permitted under standard conditions [1.1].
  • Older Adults (Geriatrics): Requires a lower initial dose as they are more susceptible to CNS effects and accumulation [1.2, 3.1].
  • Pediatric (6 months and older): Use is allowed for approved indications, with administration kept to the minimum necessary duration [1.1, 4.1].
  • Liver Impairment: Contraindicated in severe cases; caution and dose adjustment are required in mild to moderate hepatic impairment [2.1, 3.2].

Pregnancy and Lactation Status

Use during pregnancy is generally restricted and considered only when the clinical situation warrants the risk, particularly in the third trimester. Use is not recommended during breastfeeding as the drug and its metabolites are excreted into breast milk [1.2, 4.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Classification Documented Interaction Status
Highest Regulatory Restriction Co-administration with Opioids is restricted due to the official boxed warning concerning the risk of profound sedation, respiratory depression, coma, and death.
Contraindications (Conditions) Severe hepatic insufficiency is a contraindication due to impaired drug clearance. Use in infants under six months is contraindicated due to insufficient clinical experience.

Pharmacokinetic and Pharmacodynamic Interactions

The official interaction profile is defined by both pharmacodynamic and pharmacokinetic interaction patterns.

  • CNS Depression: Co-administration with substances classified as Central Nervous System (CNS) depressants, including alcohol, antipsychotics, barbiturates, and sedating antihistamines, is documented to cause additive CNS depressant effects. Simultaneous ingestion of alcohol is explicitly advised against.
  • Metabolic Alteration: Plidan is metabolized primarily by CYP2C19 and CYP3A4 enzymes. Co-administered enzyme inhibitors (e.g., cimetidine, fluoxetine) are documented to decrease the rate of elimination, resulting in increased drug exposure. Conversely, enzyme inducers (e.g., rifampin, carbamazepine) are documented to increase the rate of elimination.
  • Food and Substance Effects: The consumption of grapefruit juice is documented to increase plasma levels due to CYP enzyme inhibition. A moderate fat meal is documented to delay and decrease the extent of oral absorption.

Mechanism of Action

How Plidan Works: Mechanism of Action

The active ingredient, Diazepam, exerts its function through Positive Allosteric Modulation (PAM) of the GABA A receptor complex throughout the central nervous system. The molecule binds to an allosteric site on the receptor, specifically at the interface of the alpha and gamma subunits. This interaction increases the frequency of openings of the associated Chloride ion ( Cl^-) channel, a process that requires the presence of the endogenous neurotransmitter gamma-Aminobutyric acid ( GABA). The resulting massive influx of negative Cl^- ions causes the neuron to become hyperpolarized, making the cell less excitable.

This molecular cascade translates into a widespread, functional enhancement of inhibitory tone across key neural structures, including the limbic system, cortex, and spinal cord. The enhancement results in a systemic reduction of neuronal firing rates, dampening high-frequency signaling. This action contributes to a generalized reduction in central nervous system excitability and modulation of motor neuron activity. The mechanism's effectiveness is constrained by sustained use, which can lead to receptor downregulation or uncoupling, diminishing the capacity for signal amplification.

Dosage and Administration Information

Official Administration Instructions for Plidan (Diazepam)

Plidan is administered via several officially approved routes, and the dose and frequency are strictly determined by the form used and the clinical context (acute versus maintenance use). The available administration routes are Oral (tablet and solution), Intravenous (IV), Intramuscular (IM), Rectal (gel/solution), and Intranasal (spray).


Dosage and Frequency Patterns

For most maintenance uses, such as anxiety and muscle spasm, the oral dosage ranges from 2 mg to 10 mg taken 2 to 4 times daily. In acute, emergent situations like status epilepticus, the IV dose is typically 5 mg to 10 mg and may be repeated at 10-to-15 minute intervals up to a maximum cumulative dose of 30 mg. For acute intermittent seizure management (rectal/intranasal), use is restricted, often to no more than one episode every five days and a maximum of five episodes per month.

Treatment duration for conditions like anxiety must be kept as short as possible, generally not exceeding 8 to 12 weeks, inclusive of the tapering off process.


Procedural and Population Adjustments

Specific administration constraints apply to injectable forms. The IV solution must be injected slowly, taking at least one minute for each 5 mg (1 mL) given, and should not be mixed or diluted with other solutions. In specific patient groups, such as older adults or those who are debilitated, the initial dosage is significantly reduced to an initial range of 2 mg to 2.5 mg, once or twice daily, and increased gradually if necessary. Oral absorption is noted to be delayed and decreased when the dose is administered with a moderate fat meal.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Research

The research regarding this molecule has primarily focused on its potential role in managing acute viral infections. Initial studies evaluated the compound's effect on the time required for symptom resolution.

Research included studies examining a mechanism that involves modulation of the host immune response and direct interference with viral replication. Further investigation is necessary to fully understand this process.


Major Findings by Indication

1. Acute Respiratory Viral Infections (ARVI)

A series of randomized controlled trials (RCTs) and observational studies explored the effect of the compound on the duration and severity of ARVI symptoms in adult populations.

  • Symptom Resolution: Research has explored whether it could lead to better patient comfort, specifically regarding upper respiratory tract symptoms. Findings have been described as varied across different study cohorts in research.
  • Time to Recovery: Studies have focused on its potential effect on the rapidity of symptom changes, though definitive conclusions on rapid benefit have not been established.

2. Chronic Viral Management (CVM)

Research in chronic conditions has been less conclusive. The main focus has been on its effect when used in combination with standard care.

  • Viral Load Impact: Studies evaluated the examination of a lasting change in viral load in specific patient groups. Evidence remains limited and is not yet clear whether the compound contributes significantly to maintenance goals.
  • Combination Therapy: Studies assessed the long-term outcomes associated with the combination of the compound and existing antiviral protocols. It has been explored as an option in research within this therapeutic area.

Important Note: This information is not a substitute for professional medical assessment. Data presented here only describes what studies evaluated.

Frequently Asked Questions (FAQ)

Common questions about Plidan (FAQ)


Q: How quickly does Plidan start working?

According to the official product information, following oral administration, the average time to reach peak concentrations in the bloodstream is typically between 1 and 1.5 hours. However, the noted range in pharmacological studies extends from as little as 15 minutes to up to 2.5 hours.


Q: How long do the effects of Plidan last after taking a dose?

Plidan is classified as a long-acting medication. Its effects are sustained because the terminal elimination half-life of the active substance is noted to be up to 48 hours. Its main active metabolite has a significantly prolonged half-life, lasting up to 100 hours.


Q: What happens if I forget to take a dose of Plidan?

Official patient instructions typically state that a forgotten dose may be taken as soon as it is remembered. However, if it is already close to the time for your next scheduled dose, the official guidance is to skip the missed dose entirely and continue with your regular schedule. Two doses should not be taken simultaneously to make up for a forgotten one.


Q: Is it normal to feel a bit restless after taking Plidan?

Official safety documents note that what are called paradoxical reactions are known to occur in some patients. These uncommon reactions can involve symptoms like agitation, restlessness, and increased irritability. Official information describes these symptoms as more likely to be noted in children and older adults.


Q: Is Plidan safe for elderly people?

The official documentation requires special consideration for older adults. Due to changes in the body’s processing of the drug, this group is noted to have an increased risk of central nervous system (CNS) effects, such as sedation and difficulty with muscle coordination. These effects raise the documented risk of falls. The initial amount is often reduced and increased gradually, as determined by a healthcare provider.


Q: Does Plidan affect the ability to drive or operate machinery?

Official documents contain warnings that driving or operating heavy machinery should be avoided. This is because the medication is a CNS depressant, and its effects can cause drowsiness, dizziness, and confusion that may impair judgment or physical coordination.


Q: Can Plidan be taken on an empty stomach?

Official data on the drug’s absorption indicate that the time to reach peak concentration is faster when the medication is taken in a fasting state. Conversely, absorption is delayed and decreased when the dose is administered with a moderate fat meal.


Q: How long can a person typically take Plidan?

For indications like anxiety, the duration of treatment is described in regulatory documents as needing to be kept as short as possible, generally not exceeding 8 to 12 weeks, which includes the period needed for gradually reducing the dose. For chronic conditions, regular re-evaluation by a professional is necessary to assess the ongoing need for treatment.


Q: What are the key ingredients in Plidan besides the active substance?

The medication contains the active substance, Diazepam, along with several inactive ingredients, also known as excipients, to form the final dosage. These can include substances like anhydrous lactose, magnesium stearate, and microcrystalline cellulose in the tablet form. Specific colors are also listed for some tablet strengths.


Q: Can children or adolescents use Plidan?

Plidan is formally contraindicated (should not be used) in infants younger than 6 months of age due to lack of established safety data. For pediatric patients, which includes children and adolescents aged 6 months and older, it can be used for approved indications, with treatment duration kept to a minimum and dosage carefully overseen.


Q: What information is available about Plidan and pregnancy or breastfeeding?

Use during pregnancy is officially restricted and is generally considered only when the potential benefit outweighs the potential risk to the fetus, particularly during the third trimester. Since the drug is excreted in breast milk, official advice is that breastfeeding is not recommended while undergoing treatment.


Q: Is Plidan addictive or habit-forming?

Official documents explicitly state that Plidan carries risks of physical and psychological dependence. Its use, especially over a long period, is associated with a risk of withdrawal symptoms if the medication is stopped suddenly. It is classified as a Schedule IV controlled substance due to this potential.


Q: Is Plidan known to cause stomach upset?

Official lists of adverse reactions include effects under the category of Gastrointestinal Disorders. These documented effects include symptoms such as nausea, dry mouth, epigastric pain, and stomach pain.


Q: Does Plidan cause weight gain or weight loss?

Official patient information indicates that Plidan does not usually affect body weight. However, its effects can rarely include an effect on appetite, which could indirectly lead to changes in weight. Any significant changes in weight should be noted.


Q: Is it common to have headaches after starting Plidan?

Headaches are not consistently listed among the most common adverse reactions experienced when first starting the medication. However, official documents do note that headaches are a potential withdrawal symptom that may occur if the medication is stopped abruptly.


Q: What should I do if a side effect seems to be getting worse?

Guidance indicates that for common side effects, such as confusion, the user should maintain the prescribed regimen and consult a healthcare professional. If you experience any serious or severe symptoms, the guidance is to immediately seek emergency medical attention.


Q: Does Plidan affect sleep patterns?

Studies have noted that while Plidan is used to help promote sleep, it can alter the overall structure of sleep. Research suggests it may shorten the time taken to fall asleep and improve sleep continuity, but it can also reduce the time spent in both REM sleep and deep (slow-wave) sleep stages.


Q: Does Plidan affect laboratory blood tests?

Clinical pharmacology reports from official safety and pharmacokinetic studies noted that there were no reports of clinically significant abnormal laboratory values. This suggests the medication does not generally affect common blood test results; however, this is a summary of specific trials.


Q: Can I use Plidan if I have kidney problems?

The official product documentation indicates that a dosage reduction may be required in patients who have kidney (renal) dysfunction. The ability of the body to clear the medication can be affected, which requires careful assessment before use.


Q: Why is Plidan only available by prescription?

Plidan is restricted to prescription-only use because it is classified as a Schedule IV controlled substance by regulatory bodies. This classification reflects its known potential for misuse and dependence, meaning its use requires careful monitoring and oversight by a healthcare professional.

How should Plidan be stored and disposed of?

How to Store and Dispose of Plidan?

The storage and disposal of Plidan (Diazepam) must strictly follow official regulatory requirements to ensure product stability and safety.

Storage Conditions

Plidan must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and stored in its tightly closed original container to prevent moisture exposure.

Safety and Disposal

As a controlled substance, Plidan must be kept out of the reach of children and should be stored locked up to prevent misuse.

Disposal of unused or expired Plidan should primarily be handled through drug take-back programs. The product must not be allowed to enter drains or water courses, adhering to environmental protection rules.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plidan found in:

A-Z Index: